SCHEMBL609817

SCHEMBL609817

Cc1c(Cl)cccc1S(=O)(=O)N1CCC[C@H](C(=O)N(CC2CC2)C2CCC(O)CC2)C1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 8/20 0.57
ALDH1A1 P00352 5/20 0.47
LMNA P02545 5/20 0.47
TSHR P16473 4/20 0.47
HTT P42858 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NPSR1 Q6W5P4 3/20 0.47
ALOX15 P16050 1/20 0.47
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
POLB P06746 1/20 0.40
MAPK1 P28482 1/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4960486 1.00 HSD11B1 (0.57) HSD11B1ALDH1A1LMNATSHRHTT
SCHEMBL609816 1.00 HSD11B1 (0.57) HSD11B1ALDH1A1LMNATSHRHTT
SCHEMBL610204 0.89 TSHR (0.50) HSD11B1ALDH1A1LMNATSHRHTT
SCHEMBL610203 0.89 TSHR (0.50) HSD11B1ALDH1A1LMNATSHRHTT
SCHEMBL20456972 0.81 HSD11B1 (0.65) HSD11B1ALDH1A1HTTTP53MAPT
SCHEMBL4963055 0.79 HSD11B1 (0.85) HSD11B1RAB9A
SCHEMBL609710 0.79 HSD11B1 (0.85) HSD11B1RAB9A
SCHEMBL609711 0.79 HSD11B1 (0.85) HSD11B1RAB9A
SCHEMBL610185 0.79 HSD11B1 (0.85) HSD11B1RAB9A
SCHEMBL5243753 0.78 HSD11B1 (0.72) HSD11B1TSHRTP53MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040964-A1 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-02-16 US claimed
US-20060004049-A1 N-substituted piperidines and their use as pharrmaceuticals INCYTE CORPORATION 2006-01-05 US claimed
US-8288417-B2 N-substituted piperidines and their use as pharmaceuticals INCYTE CORPORATION (US) 2012-10-16 US disclosed
US-20120040964-A1 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-02-16 US disclosed
US-8071624-B2 N-substituted piperidines and their use as pharmaceuticals INCYTE CORPORATION (US) 2011-12-06 US disclosed
EP-1758580-A4 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-16 EP disclosed
EP-1758580-A2 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-03-07 EP disclosed
WO-2006012226-A2 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20060004049-A1 N-substituted piperidines and their use as pharrmaceuticals INCYTE CORPORATION 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040964-A1 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS HSD11B1, CYP11B1, HSD3B1 HSD11B1 1/4885ALDH1A1 57/4885LMNA 2501/4885
US-20060004049-A1 N-substituted piperidines and their use as pharrmaceuticals HSD11B1, HSD3B1, HSD11B2 HSD11B1 1/4885ALDH1A1 76/4885LMNA 2826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.